anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Large Vessel Occlusion (LVO) screening tools provide objective assessments to guide diagnostic decisions during acute stroke activations. The Stroke VAN screening tool includes weakness, vision, aphasia, and neglect; however, only screens positive if weakness is present regardless of presence of other symptoms including isolated aphasia. The purpose of this project was to evaluate wAve, a modified Stroke VAN screening tool. WAve includes components of VAN with emphasis on isolated aphasia.
METHODS: We conducted a retrospective cohort study on 376 persons who presented with stroke symptoms within 24 h of last known well (LKW) to the Emergency Department of an urban comprehensive stroke center in north central Texas between July 2019 and January 2020. Comparison of VAN and wAve predictive values was calculated using Chi square analysis. Sensitivity and specificity was checked by using MedCalc software. Data from the electronic medical record was obtained for analysis including a documented wAve score and a calculated VAN score. Results of CT angiogram diagnostic testing was used to determine congruence of screening results with evidence of LVO. Power analysis described by Hajian- Tilaki was used to estimate study size.
RESULTS: Results included 192 positive wAve screens and 184 negative wAve screens compared to 152 positive VAN screens and 224 negative VAN screens. The sensitivities for wAve and VAN were 89 % and 80 % respectively. Negative predictive values for wAve and VAN were 97 % and 95 % respectively. In isolated aphasic person, one of eight presented with a LVO and received intervention.
CONCLUSION: The team discovered more LVOs were identified with wAve than VAN in persons exhibiting isolated aphasia symptoms. Larger studies are needed to understand the role isolated aphasia plays in LVO detection.
The solution should be protected from light. Do not use the injection if its color is pinkish or darker than slightly yellow or if it contains a precipitate.

Do not administer unless solution is clear and seal is intact. 

Discard unused portion.

Although epinephrine can produce ventricular fibrillation, its actions in restoring electrical activity in asystole and in enhancing defibrillation of the fibrillating ventricle are well documented. The drug, however, should be used with caution in patients with ventricular fibrillation.

In patients with prefibrillatory rhythm, intravenous epinephrine must be used judiciously with extreme caution because of its excitatory action on the heart. Since the myocardium is sensitized to this action of the drug by many anesthetic agents, epinephrine may convert asystole to ventricular fibrillation if used in the treatment of anesthetic cardiac accidents.

Epinephrine should be used cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias. All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.

Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity. Combined effects may induce serious cardiac arrhythmias. They may be administered alternately when the preceding effect of other such drug has subsided.

Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia. (See CONTRAINDICATIONS). When encountered, such arrhythmias may respond to administration of a beta-adrenergic blocking drug. Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs. 

Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.

Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.

Pregnancy Category C. Animal reproduction studies have not been conducted with epinephrine. It is also not known whether epinephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Epinephrine should be given to a pregnant woman only if clearly needed. 

Labor and Delivery. Parenteral administration of epinephrine if used to support blood pressure during low or other spinal anesthesia for delivery can cause acceleration of fetal heart rate and should not be used in obstetrics when maternal blood pressure exceeds 130/80. (See CONTRAINDICATIONS).
PURPOSE:To obtain the titled inhibitor useful for the therapeutic treatment of complications of diabetes, e.g. corneal dysraphism, cataract, neuropathy, retinopathy and renal disorder, especially cataract and neuropathy, by using a specific quinazoline derivative as an active component. CONSTITUTION:The objective agent contains, as an active component, a quinazoline derivative of formula I [R<1> is H, halogen or lower alkoxy; R<2> is dihalophenyl(lower)alkyl; Z is lower alkylene], e.g. 2-[3-(3,4-dichlorobenzyl)-1,2,3,4- tetrahydro-2,4-dioxoquinazolin-1-yl]acetic acid,or its pharmacologically allowable salt. The compound of formula I can be produced by reacting a compound of formula II or its salt with a compound of formula III [R<3> is (protected) carboxy; X is eliminable group] or its salt in a solvent in the presence of an organic or inorganic base and hydrolyzing the reaction product. It is administered at a rate of 0.1-100mg of the active component per 1kg of body weight per dose.
PURPOSE: To obtain a carcinogenesis-inhibiting agent containing a hydrogenated condensed ring hydrocarbon of specific structure as an active ingredient and capable of inhibiting the carcinogenesis induced by a carcinogenic organic compound without accompanied by side effects. CONSTITUTION: The carcinogenesis-inhibiting agent contains a bicyclic or tricyclic hydrogenated condensed cyclic hydrocarbon having at least a condensed benzene ring and a 4-8 membered ring corresponding to the condensed ring hydrocarbon on the structure of the molecule as an active ingredient. The hydrogenated condensed ring hydrocarbon used as the active ingredient is a hydrogenated phenanthrene (e.g. 1,2,3,4,5,6,7,8-octahydrophenanthrene), a hydrogenated anthracene (e.g. 1,2-dihydroanthracene), a hydrogenated naphthalene (e.g. 1,2- dihydronaphthalene), etc. The active ingredient is most preferably orally administered The dose of the active ingredient is preferably 10-700mg/day/kg of the body weight of a living body.
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, namely to a vaccine for stimulating an immune response to target pathogens, containing a virus-like particle (VLP) based on a protein of the bovine immunodeficiency virus group antigen (Bgag), wherein the Bgag VLP comprises one or several different target pathogen proteins. Produced is a transfer vector plasmid for producing a vaccine, containing the bovine immunodeficiency virus gag gene ("Bgag gene"), one or several genes encoding one or several different target pathogen proteins, and one or more promoters, wherein said one or several genes encoding target pathogen proteins comprise a gene encoding a trans-membrane protein. Claimed is a method for preventing or suppressing the disease caused by the target pathogen in an animal by introducing an effective amount of vaccine. Claimed is a method for producing a vaccine for stimulating an immune response to the target pathogens, including the following stages: cloning the transfer vector of the described Bgag gene and the described gene encoding a target pathogen protein into a plasmid, wherein each gene is controlled by a promoter; preparing a carrier virus using said transfer vector plasmid; infecting a eukaryotic cell with said carrier virus to create the Bgag VLP; mixing an effective amount of the produced Bgag VLP with one or several adjuvants suitable for administration of the vaccine. Claimed is a method for identifying patients previously injected with the vaccine. The method includes the stages of measuring whether the Bgag gene or the Bgag protein is present in the patient and correlating a previous vaccination with the presence of the Bgag gene or the Bgag protein.EFFECT: invention provides a possibility to produce a vaccine containing recombinant virus-like particles (VLP) of a protein of the bovine protein immunodeficiency virus group antigen ("Bgag") containing one or several different types of target pathogen proteins.42 cl, 2 tbl, 41 dwg, 21 ex
The present invention relates to a composition for skin regeneration, anti-wrinkling, antioxidant, anti-inflammatory and skin whitening activities. According to the present invention, n-butylidenephthalide promotes collagen synthesis of fibroblasts in the skiin and thus has effects of regenerating skin and reducing wrinkles. N-butylidenephthalide inhibits generation of free radicals and thus has an anti-oxidant effect. N-butylidenephthalide also inhibits synthesis of melanin and thus has a skin whitening effect. Therefore, the composition can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition includes a compound represented by chemical formula 1 as an active ingredient.
This pilot study is an experimental investigation designed so that consenting subjects are randomly assigned to pharmacotherapeutic or psychotherapeutic interventions for depression.

For the initial phase of treatment, subjects will be randomly assigned to treatment with an SSRI, (escitalopram oxalate or citalopram hydrobromide), or with interpersonal psychotherapy (IPT). Escitalopram will be prescribed for all patients randomized to the medication arm of the study, unless the study psychiatrist determines that citalopram is more clinically appropriate. Escitalopram and citalopram are FDA-Approved SSRI antidepressants indicated for the treatment of depression. In order to optimize outcomes and emulate usual clinical practice, subjects who do not meet response criteria (defined as a 50% reduction in baseline Hamilton Rating Scale for Depression \[HRS-D\]) or meet stabilization criteria (defined as a mean HRS-D \< 7 for 3 weeks) at acute phase Visit 7 or Visit 13 of treatment will have the other treatment added. Subjects who meet stabilization criteria (mean HRS-D \< 7 for 3 weeks) at any time between acute phase Visit 13 and 21 will enter the 6-month continuation phase and continue with the treatment that led to their stabilization. Subjects who have not met stabilization criteria by acute phase Visit 21 will remain in active treatment and be offered alternative pharmacotherapy. Subjects who have not responded by acute phase Visit 32 will be discontinued from the protocol and referred for alternative treatment and care.
<P>PROBLEM TO BE SOLVED: To provide an angiotensin converting enzyme inhibitor obtained by extracting barley roots, an industrial waste on the production of beer, with a water-soluble solvent, and to provide a method for producing the same.  <P>SOLUTION: (1) This angiotensin converting enzyme inhibitor uses the root portion of a gramineous plant or the extract of the root portion as a raw material. The angiotensin converting enzyme inhibitor is useful for hypotensive agents and agents for preventing or treating hypertension. (2) The method for producing the angiotensin converting enzyme inhibitor is characterized by extracting the root portion of the gramineous plant with water or a water-soluble organic solvent. The inhibitor may be added to drinks, foods and medicines. The active ingredient can be purified in various purities by applying the proper combination of a precipitation method using an organic solvent such as ethanol, a mol. wt. fractionation method, an activated carbon filtration method, a cation and anion exchange resin treatment and an adsorbing treatment using an adsorbing material such as octadecylsilica.  <P>COPYRIGHT: (C)2004,JPO
Volunteers aged from 18 years to over 60 years were selected without compromise. The tests were performed in a single session lasting 1 hour where the volunteers will do the tests on the force platform.
PURPOSE:To provide ink which has excellent dispersibility and lubricity and can prevent the sinking of ball, the blurring of handwriting and squeaking when used as a ball piont pen ink, by incorporating an acrylic emulsion and a water-soluble amine salt of a high-molecular carboxylic acid in a water-based pigment ink. CONSTITUTION:A water-based pigment ink is obtd. by incorporating an acrylic emulsion (contg. carboxyl groups as hydrophilic group and having a carboxyl group content of 1.0-10.0wt%) and a water-soluble amine salt of a 10-20C carboxylic acid (e.g. diethanolamine salt of capric acid) in a water-based pigment ink. The pigment ink has excellent dispersibility and lubricity and can prevent the sinking of ball, the blurring of handwriting and squeaking when used as a ball point pen ink.
Knee osteoarthritis is the most common arthritis. Such disease is complicated by many musculoskeletal dysfunction such as disturbed joint position sense, which impairs their ability to perform their regular daily activities. As rehabilitation should target impairment in function, it is essential that therapists assess joint sense during baseline and follow-up evaluation of patients to decide on needed therapeutic interventions. Joint position sense can be assessed by various methods such as motion tracking systems and the isokinetic dynamometer, yet these equipment are expensive and are not readily available at regular clinical settings.

Smartphone has been introduced as an assessment tool in rehabilitation of musculoskeletal disorders. For the knee joint, smartphone has been validated for measuring range of motion and joint position sense in healthy population, yet it has never been validated in patients with knee osteoarthritis. Therefore, this study will investigate smartphone validity and reliability as an assessment tool of knee position sense in patients with knee osteoarthritis.
BACKGROUND: Patients with stimulant use disorder experience high rates of relapse. While neurobehavioral mechanisms involved in initiating drug use have been studied extensively, less research has focused on relapse.
METHODS: To assess motivational processes involved in relapse and diagnosis, we acquired functional magnetic resonance imaging responses to nondrug (monetary) gains and losses in detoxified patients with stimulant use disorder (n = 68) and community control participants (n = 42). In a prospective multimodal design, we combined imaging of brain function, brain structure, and behavior to longitudinally track subsequent risk for relapse.
RESULTS: At the 6-month follow-up assessment, 27 patients remained abstinent, but 33 had relapsed. Patients with blunted anterior insula (AIns) activity during loss anticipation were more likely to relapse, an association that remained robust after controlling for potential confounds (i.e., craving, negative mood, years of use, age, and gender). Lower AIns activity during loss anticipation was associated with lower self-reported negative arousal to loss cues and slower behavioral responses to avoid losses, which also independently predicted relapse. Furthermore, AIns activity during loss anticipation was associated with the structural coherence of a tract connecting the AIns and the nucleus accumbens, as was functional connectivity between the AIns and nucleus accumbens during loss processing. However, these neurobehavioral responses did not differ between patients and control participants.
CONCLUSIONS: Taken together, the results of the current study show that neurobehavioral markers predicted relapse above and beyond conventional self-report measures, with a cross-validated accuracy of 72.7%. These findings offer convergent multimodal evidence that implicates blunted avoidance motivation in relapse to stimulant use and may therefore guide interventions targeting individuals who are most vulnerable to relapse.
FIELD: organic chemistry and technology. SUBSTANCE: method involves dissolving camphor in acetic anhydride at mass ratio of components = (1:1)- (1:2.5), its sulfonation, separation of crystals from mother liquor, washing out a product followed by drying and additional recrystallization of product from acetic acid. Camphor is dissolved in a mixture of acetic anhydride and sulfonation mother liquor at mass ratio of components = (1:1:0.1)-(1:2:4). The use of d,l-camphor ensures to decrease cost production of sulfocamphoric acid by 5-10-fold, increase the yield of ready product by 1.5-fold, decrease consumption coefficients by 9-42%. Synthesized compound is used in chemical-pharmaceutical industry for production of drugs (sulfocaine, semisynthetic penicillins, cephalosifins and others) that show coronary-dilating, antibacterial and analgetic activity. EFFECT: increased yield, decreased cost, broadened assortment, improved quality of the end product, improved ecology.
Only few years after the first report on diagnosing acute pulmonary embolism (PE) with pulmonary angiography, studies began to investigate the effectiveness and safety of thrombolytic therapy for achieving early reperfusion. In 1992, Guy Meyer demonstrated the fast improvement of pulmonary haemodynamics after alteplase administration; this drug has remained the mainstay of thrombolysis for PE over almost 35 years. In the meantime, algorithms for PE risk stratification continued to evolve. The landmark Pulmonary Embolism International Thrombolysis (PEITHO) trial, led by Guy Meyer, demonstrated the clinical efficacy of thrombolysis for intermediate-risk PE, albeit at a relatively high risk of major, particularly intracranial bleeding. Today, systemic thrombolysis plays an only minor role in the real-world treatment of acute PE in the United States and Europe, but major trials are underway to test safer reperfusion regimens. Of those, the PEITHO-3 study, conceived by Guy Meyer and other European and North American experts, is an ongoing randomised, placebo-controlled, double-blind, multinational academic trial. The primary objective is to assess the efficacy of reduced-dose intravenous thrombolytic therapy against the background of heparin anticoagulation in patients with intermediate-high-risk PE. In parallel, trials with similar design are testing the efficacy and safety of catheter-directed local thrombolysis or mechanical thrombectomy. Increasingly, focus is being placed on long-term functional and patient-reported outcomes, including quality of life indicators, as well as on the utilization of health care resources. The pioneering work of Guy Meyer will thus continue to have a major impact on the management of PE for years to come.
The 'reduce sitting' intervention group will receive three in-person health coaching sessions followed by five counseling phone calls. Participants will wear a thigh worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. At each in-person health coaching session participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. In addition to the three initial in-person counseling sessions using the ActivPAL feedback, participants will receive phone calls from the health educator biweekly to help overcome barriers, to work on self-monitoring and planning skills, and to prepare relapse prevention. Tools to help prompt standing, including a standing desk, will also be provided.
Hydrocodone: Serious overdose with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis). extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.

Acetaminophen: In acetaminophen overdosage: dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necrosis, hypoglycemic coma and thrombocytopenia may also occur.

Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.

In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 grams and fatalities with less than 15 grams.
Patients were titrated for relevant parameters of noninvasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the noninvasive bi-level positive pressure mode, and the highfrequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors. There is an urgent need to find more effective drugs that inhibit NSCLC. Fargesin (FGS) has demonstrated anti-tumor effects; however, its efficacy and the molecular mechanism of inhibiting NSCLC are unclear. Herein, we investigated FGS' inhibitory effects on NSCLC by CCK8 and EdU assays and cell cycle analysis of A549 cells in vitro and in a nude mouse tumor transplantation model in vivo. FGS (10-50 μM) significantly inhibited cell proliferation and down-regulated expression levels of CDK1 and CCND1. Transcriptomic analysis showed that FGS regulated the cell metabolic process pathway. Differential metabolites with FGS treatment were enriched in glycolysis and pyruvate pathways. Cell metabolism assay were used to evaluate the oxygen consumption rate (OCR), Extracellular acidification rate (ECAR) in A549 cells. FGS also inhibited the production of cellular lactate and the expression of LDHA, LDHB, PKM2, and SLC2A1. These genes were identified as important oncogenes in lung cancer, and their binding to FGS was confirmed by molecular docking simulation. Notably, the over-expression and gene silencing experiments signified PKM2 as the molecular target of FGS for anti-tumorigenesis. Moreover, the H3 histone lactylation, were correlated with tumorigenesis, were inhibited with FGS treatment. Conclusively, FGS inhibited the aerobic glycolytic and H3 histone lactylation signaling pathways in A549 NSCLC cells by targeting PKM2. These findings provide evidence of the therapeutic potential of FGS in NSCLC.
All participants complete six weeks of TMS treatment (five days per week) within the UCLA TMS Clinic. Participants in this condition additionally access iCBT materials and attend a weekly session for 30 minutes with a trained mental health coach to discuss iCBT content.
Estradiol gel, 0.06% 1.25 g per day is the single approved dose for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. The lowest effective dose of estradiol gel, 0.06% for this indication has not been determined. When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products.

Before using the canister for the first time, it must be primed. Remove the large canister cover, and fully depress the pump 5 times. Discard the unused gel by thoroughly rinsing down the sink or placing it in the household trash. After priming, the pump is ready to use.

The recommended area of application is the arm. Apply a thin layer over the entire arm on the inside and outside from wrist to shoulder.